Electronic Logs - The next phase of execution maturity in pharma
LYMPHOMA TREATMENT AT A CROSSROADS
Elevating Drug Safety
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
Maximising Patient Engagement in Clinical Trials
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
mRNA Platforms as Diagnostics and Therapeutics for Human Infertility Treatments
Associate Professor, Department of Biology, Khalifa University
Junaid Kashir is an Associate Professor in the Department of Biology at Khalifa University and
has previously chaired multiple researchadministrative committees He has been heavily
involved in multiple programs for training graduate clinical embryology students Dr Kashirs
research aims to develop therapeuticdiagnostic interventions to treat infertility and understand
embryology
Articles
Metabolic Stability
The liability of a drug substance to the metabolism is referred to as metabolic stability The liver uses CYPmediated metabolism to clear most orally administered drugs Metabolic stability data is essential for evaluating and optimising the human therapeutic dose for the drug In vitro systems obtained fromthe human liver such as microsomes and hepatocytes
Research Insights
Linking Spatial Drug Heterogeneity to Microbial Growth Dynamics in Theory and Experiment
Drugs play a central role in limiting bacterial population spread yet laboratory studies typically assume wellmixed environments when assessing microbial drug responses In contrast bacteria in the human body
Case Studies
Quality Management In Clinical Trials: An Observational Case Study By Pfizer
Abstract Clinical trials are conducted to collect the data necessary to provide information for academia industry and regulators to make decisions about the safety and efficacy of the disease illness or preventative medicines under study To ensure investigators are following the protocol complying with regulatory and G
Techno Trends
Portola Pharmaceuticals Introduces Antidote for the Reversal of Factor Xa Inhibitors
Portola Pharmaceuticals develops Andexxa coagulation factor Xa recombinant inactivatedzhzo the first and only antidote indicated for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to lifethreatening or uncontrolled bleeding Andexxas rapid reversal of the anticoagulating effects of rivaroxaban and apixaban will help cli...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Single Domain Antibody
Dr. Marco Pirisinu graduated from the University of Sassari, Italy, with a degree in Biomedical Sciences focusing on the novel design and application of cell penetrating peptide targeting mitochondria. He has more than 10 years of research experience working with academic institutions and biotechnology companies. His primary research interest are nanomedicine, targeted therapy and drug delivery systems. Dr. Pirisinu is first author and corresponding author of peer reviewed articles and Guest Editor forSCI-indexed journals. He is currently Senior Scientist at City University of Hong Kong and Head of Innovative Product Development at Jotbody (HK) Limited.
Dr. Likun Wei obtained his BEng from Tianjin University of Technology, majoring in computer science and MSA from Shanghai Ocean University, majoring in agriculture.He completed his PhD in Biomedical Sciences at City University of Hong Kong in 2021. His PhD work demonstrated a small shark model for affordable high affinity sdAb production.He has co-authored 12 publications in SCI-indexed journals including Nature Communications, Bioresource Technology, Journal of Extracellular Vesicles, Iscience, The Journal of Immunology, and Frontiers in Bioengineering and Biotechnology. Dr. Likun Wei is currently R&D Lead at Jotbody (HK) Limited.
Detangling the Diagnostic Odyssey in Neurodevelopmental Disorder by Genomic Consultancy
Emili is a well-known genetic consultant with vast experience in cytogenetics, molecular biology with special emphasis in neurobiology. She is doing human genetics for past 22 years and now is practising genetic counselling as well as continuing her passion for research.
Koutilya basically is an academician in Zoology and has research interest in areas like anti-microbial peptides of amphibians, bio-active components of amphibians and genetic aspects of human reproductive disorder.
A BITTER PILL: Exploring the Realm of Drug Counterfeiting
Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Rethinking How Medicines Work
Dr. Asawari Pagare is a bioinformatician at UW Medicine where she studies the genomics of myositis, an autoimmune disease that is not yet well understood. She earned her PhD in Chemistry from the University of North Carolina at Chapel Hill, USA, where she explored how timing and fluctuations influence how living systems interpret signals relevant to medicine.
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
